Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization - Total: 2023-2025

Historic Depreciation & Amortization - Total for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2025 value amounting to $50,204.

  • InMed Pharmaceuticals' Depreciation & Amortization - Total rose 124.37% to $12,206 in Q2 2025 from the same period last year, while for Jun 2025 it was $50,204, marking a year-over-year increase of 5.16%. This contributed to the annual value of $50,204 for FY2025, which is 5.16% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Depreciation & Amortization - Total stood at $50,204 for FY2025, which was up 5.16% from $47,742 recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization - Total peaked at $50,204 during FY2025, and registered a low of $39,613 during FY2023.
  • In the last 3 years, InMed Pharmaceuticals' Depreciation & Amortization - Total had a median value of $47,742 in 2024 and averaged $45,853.
  • Data for InMed Pharmaceuticals' Depreciation & Amortization - Total shows a peak YoY increased of 20.52% (in 2024) over the last 5 years.
  • Over the past 3 years, InMed Pharmaceuticals' Depreciation & Amortization - Total (Yearly) stood at $39,613 in 2023, then increased by 20.52% to $47,742 in 2024, then climbed by 5.16% to $50,204 in 2025.